SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

Concentrations of Credit Risk and Significant Customers

The following table summarizes customers that represent 10% or greater of our consolidated total gross revenues:

	Year Ended December 31,
	2023		2022		2021
Distributor A	28	%	33	%	27	%
Roche	15	%	*		*
Regeneron Pharmaceuticals	*		*		11%

__________________________________________

*Represents less than 10% and/or not a customer in the applicable year

The following table summarizes customers with amounts due that represent 10% or greater of our consolidated gross accounts receivable balance:

	As of December 31,
	2023		2022
Novartis AG	18	%	*
Distributor A	16	%	32	%
Distributor B	*		10	%

__________________________________________

*Represents less than 10%

Estimated Useful Lives of Property, Plant and Equipment

The estimated useful lives of property, plant and equipment are as follows:

Asset Category	Useful Life
Laboratory equipment	5
Computer equipment and software	3-10 years
Furniture and fixtures	5
Leasehold improvements	Shorter of asset life or lease term
Manufacturing Equipment	7-15 years
Buildings	40 years

Common Shares Excluded from the Calculation of Net Loss Per Common Share

The following table sets forth the potential common shares (prior to consideration of the treasury stock or if-converted methods) excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive: 

	As of December 31,
(In thousands)	2023	2022	2021
Options to purchase common stock, inclusive of performance-based stock options	7,422	8,424	10,015
Unvested restricted common stock, inclusive of performance-based restricted common stock	2,058	1,487	1,210
Convertible debt	3,616	3,616	—
Total	13,096	13,527	11,225